Literature DB >> 1860224

Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor.

E J Haskel1, S R Torr, K C Day, M O Palmier, T C Wun, B E Sobel, D R Abendschein.   

Abstract

BACKGROUND: This study was designed to determine whether arterial reocclusion after thrombolysis can be prevented by lipoprotein-associated coagulation inhibitor (LACI), a physiological inhibitor of tissue factor-induced coagulation mediated by the extrinsic pathway. METHODS AND
RESULTS: Thrombosis was induced in femoral arteries of anesthetized dogs with the use of anodal current to elicit extensive vascular injury and formation of platelet-rich thrombi in one artery and with thrombogenic copper wire to elicit fibrin-rich thrombi without appreciable vascular injury in the contralateral artery. Recanalization of both vessels was induced with t-PA (1.7 mg/kg i.v. over 1 hour) and verified with Doppler flow probes. Reocclusion occurred within 2 hours in seven of seven arteries with electrical injury-induced thrombosis and in four of seven arteries with copper wire-induced thrombosis in the absence of LACI. In dogs given infusions of recombinant DNA-produced LACI (225 micrograms/kg over 15 minutes, followed by 4 micrograms/kg/min i.v.) after completion of the infusion of t-PA, no reocclusion occurred during the 2-hour interval of observation in any of the five arteries subjected to electrical injury (p less than 0.001), and cyclic partial occlusions were nearly abolished (0.4 +/- 0.4/hr in LACI-treated dogs compared with 13.7 +/- 5.5/hr in saline-treated dogs, p less than 0.0001). In contrast, reocclusion occurred in two of five arteries with indwelling copper wires, and cyclic partial occlusions were unaffected despite LACI. LACI prolonged the partial thromboplastin time modestly (1.7 +/- 0.2 x baseline) but did not affect platelet counts or aggregation assessed ex vivo.
CONCLUSIONS: Inhibition of the extrinsic pathway of coagulation with LACI prevents thrombotic arterial reocclusion after thrombolysis in vessels subjected to extensive vascular injury. Our results demonstrate that activation of the extrinsic pathway plays a critical role in thrombotic reocclusion and that LACI provides a highly targeted approach to facilitate sustained recanalization without directly inhibiting platelets.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860224     DOI: 10.1161/01.cir.84.2.821

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  16 in total

1.  Enhancing Thrombolysis with Adjunctive Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

2.  Achieving Optimal Reperfusion without Adjunctive Antithrombotic Therapy: Novel Thrombolytic Dosing Strategies.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Coronary Artery Patency and Survival in Clinical Trials.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 4.  Developments in antithrombotic therapy: state of the art anno 1996.

Authors:  H ten Cate; M T Nurmohamed; J W ten Cate
Journal:  Pharm World Sci       Date:  1996-12

5.  Coronary artery mapping: a method for three-dimensional reconstruction of epicardial anatomy.

Authors:  C M Speidel; R K Walkup; D R Abendschein; J L Kenzora; M W Vannier
Journal:  J Digit Imaging       Date:  1995-02       Impact factor: 4.056

6.  Determination of the disulfide bond pairings in human tissue factor pathway inhibitor purified from Escherichia coli.

Authors:  B N Violand; M R Schlittler; K L Duffin; C E Smith
Journal:  J Protein Chem       Date:  1995-07

Review 7.  Novel antithrombotic drugs in development.

Authors:  M Verstraete; P Zoldhelyi
Journal:  Drugs       Date:  1995-06       Impact factor: 9.546

8.  Optimizing human apyrase to treat arterial thrombosis and limit reperfusion injury without increasing bleeding risk.

Authors:  Douglas Moeckel; Soon Soeg Jeong; Xiaofeng Sun; M Johan Broekman; Annie Nguyen; Joan H F Drosopoulos; Aaron J Marcus; Simon C Robson; Ridong Chen; Dana Abendschein
Journal:  Sci Transl Med       Date:  2014-08-06       Impact factor: 17.956

9.  Recombinant soluble human tissue factor secreted by Saccharomyces cerevisiae and refolded from Escherichia coli inclusion bodies: glycosylation of mutants, activity and physical characterization.

Authors:  M J Stone; W Ruf; D J Miles; T S Edgington; P E Wright
Journal:  Biochem J       Date:  1995-09-01       Impact factor: 3.857

10.  The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor.

Authors:  I Warshawsky; G J Broze; A L Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.